These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 38824623)

  • 41. Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.
    Lin J; Wong B; Offord S; Mirski D
    J Behav Health Serv Res; 2013 Jul; 40(3):355-66. PubMed ID: 23579871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.
    Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ
    JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.
    Carswell C; Wheeler A; Vanderpyl J; Robinson E
    Clin Drug Investig; 2010; 30(11):777-87. PubMed ID: 20712387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia.
    Fu AZ; Pesa JA; Lakey S; Benson C
    BMC Psychiatry; 2022 Apr; 22(1):250. PubMed ID: 35395757
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
    Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
    [No Abstract]   [Full Text] [Related]  

  • 46. Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2020 Apr; 40(4):355-375. PubMed ID: 32152867
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study.
    Basu A; Benson C; Turkoz I; Patel C; Baker P; Brown B
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1086-1095. PubMed ID: 36125055
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study.
    Miura G; Misawa F; Kawade Y; Fujii Y; Mimura M; Kishimoto T
    J Clin Psychopharmacol; 2019; 39(5):441-445. PubMed ID: 31415288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis.
    Okoli CTC; Kappi A; Wang T; Makowski A; Cooley AT
    Int J Ment Health Nurs; 2022 Jun; 31(3):469-535. PubMed ID: 34931437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study.
    Korkmaz ŞA; Gürler S
    Curr Med Res Opin; 2024 May; 40(5):855-861. PubMed ID: 38557295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports.
    Guinart D; Misawa F; Rubio JM; Pereira J; Sharma H; Schoretsanitis G; Kane JM; Correll CU
    J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33238083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics: A Retrospective Chart Review and Prescribers' Attitude Survey.
    Misawa F; Amemiya A; Fujii Y; Takeuchi H
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):81-86. PubMed ID: 34668878
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of long-acting injectable
    Vita G; Tavella A; Ostuzzi G; Tedeschi F; De Prisco M; Segarra R; Solmi M; Barbui C; Correll CU
    Ther Adv Psychopharmacol; 2024; 14():20451253241257062. PubMed ID: 38831918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study.
    Rubio JM; Taipale H; Correll CU; Tanskanen A; Kane JM; Tiihonen J
    Psychol Med; 2020 Jun; 50(8):1356-1367. PubMed ID: 31190660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
    Rosenheck RA; Leslie DL; Sint KJ; Lin H; Li Y; McEvoy JP; Byerly MJ; Hamer RM; Swartz MS; Stroup TS
    Psychiatr Serv; 2016 Oct; 67(10):1124-1130. PubMed ID: 27247177
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics.
    Kheloussi S; Oberlin J; Trauger M; Testa ND
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1130-1137. PubMed ID: 36125056
    [No Abstract]   [Full Text] [Related]  

  • 58. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
    MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
    Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.